-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 18, Shanghai Pharmaceuticals announced that Xinyi Wanxiang, a subsidiary of the company, recently received the "Drug Supplementary Application Approval Notice" issued by the State Food and Drug Administration on simvastatin tablets (10mg, 20mg), and the drug passed Consistency evaluation of the quality and efficacy of generic drugs.
Simvastatin tablets are mainly suitable for pediatric patients with hyperlipidemia, coronary heart disease, and heterozygous familial hypercholesterolemia.
As of the date of this announcement, the main manufacturers of the drug in China are Hanhui Pharmaceutical Co.